GLP1R and chronic kidney disease: All patients with T2D and CKD or at high risk for CKD, regardless of glycemic control, should be treated with sodium–glucose cotransporter 2 inhibitors (SGLT2i) or with glucagon-like peptide 1 receptor agonist (GLP1RA) semaglutide [31].